Meet the Provider
Dr. Michael Bloch is a board-certified internal medicine physician and nationally recognized expert in hypertension, vascular medicine, lipid disorders, and cardiovascular risk reduction. He serves as Medical Director of Anticoagulation and Vascular Medicine Services at Renown Health and is a Clinical Associate Professor at the University of Nevada, Reno School of Medicine. With more than 25 years of experience, Dr. Bloch specializes in the prevention, diagnosis, and treatment of complex cardiovascular conditions, including high blood pressure, peripheral vascular disease, cholesterol disorders, blood clotting conditions, and cardiovascular risk management. He is board certified in Internal Medicine, Clinical Hypertension, Clinical Lipidology, and Vascular Medicine. Dr. Bloch earned his medical degree from Georgetown University School of Medicine and completed his residency and fellowship training at New York Presbyterian Hospital–Cornell University Medical Center. He has authored numerous peer-reviewed publications and has served in leadership roles with the American Heart Association, the National Lipid Association, and several national cardiovascular organizations. Dr. Bloch is committed to helping patients achieve better cardiovascular health through evidence-based care, preventive medicine, and personalized treatment plans that address each patient's unique risk factors and goals.
Affiliated Groups
Specialties
- Internal Medicine - Cardiovascular Medicine
Areas of Expertise
- Vascular Medicine
- Lipid Management
- Resistant Hypertension Management
Locations
Education
Medical School • 1994
Georgetown University Medical School
Residency • 1997
New York Presbyterian Hospital, Cornell University Medical Center
Internal Medicine
Fellowship • 1999
New York Presbyterian Hospital, Cornell University Medical Center
Internal Medicine
Research Interests
- Principal Investigator, Olipsaran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial
- Principal Investigator, The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension (Radiance II)
- Principal Investigator, CALM-2: Controlling and Lowering Blood Pressure with the Mobius HD
- Principal Investigator, RADIANCE TRIO Hypertension: A Study of the ReCor medical Paradise System in Clinical Resistant Hypertension
- Principal Investigator, RADIANCE SOLO Hypertension: A Study of the ReCor medical Paradise System in Clinical Hypertension
Publications
- Changes in blood pressure after crossover to ultrasound renal denervation.
- 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.
- Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
- Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta-Analysis
- Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial